IL132810A0 - Tartrate salt of a substituted dipeptide as growth hormone secretagogue - Google Patents

Tartrate salt of a substituted dipeptide as growth hormone secretagogue

Info

Publication number
IL132810A0
IL132810A0 IL13281098A IL13281098A IL132810A0 IL 132810 A0 IL132810 A0 IL 132810A0 IL 13281098 A IL13281098 A IL 13281098A IL 13281098 A IL13281098 A IL 13281098A IL 132810 A0 IL132810 A0 IL 132810A0
Authority
IL
Israel
Prior art keywords
growth hormone
tartrate salt
hormone secretagogue
substituted dipeptide
dipeptide
Prior art date
Application number
IL13281098A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Priority to IL16067898A priority Critical patent/IL160678A0/xx
Priority to IL16067798A priority patent/IL160677A0/xx
Priority to IL16067998A priority patent/IL160679A0/xx
Priority to IL16067698A priority patent/IL160676A0/xx
Publication of IL132810A0 publication Critical patent/IL132810A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
IL13281098A 1997-06-25 1998-06-05 Tartrate salt of a substituted dipeptide as growth hormone secretagogue IL132810A0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IL16067898A IL160678A0 (en) 1997-06-25 1998-06-05 Tartrate salt of a substituted dipeptide as growth hormone secretagogue
IL16067798A IL160677A0 (en) 1997-06-25 1998-06-05 Tartrate salt of a substituted dipeptide as growth hormone secretagogue
IL16067998A IL160679A0 (en) 1997-06-25 1998-06-05 Tartrate salt of a substituted dipeptide as growth hormone secretagogue
IL16067698A IL160676A0 (en) 1997-06-25 1998-06-05 Tartrate salt of a substituted dipeptide as growth hormone secretagogue

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5072397P 1997-06-25 1997-06-25
PCT/IB1998/000874 WO1998058948A1 (en) 1997-06-25 1998-06-05 Tartrate salt of a substituted dipeptide as growth hormone secretagogue

Publications (1)

Publication Number Publication Date
IL132810A0 true IL132810A0 (en) 2001-03-19

Family

ID=21966996

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13281098A IL132810A0 (en) 1997-06-25 1998-06-05 Tartrate salt of a substituted dipeptide as growth hormone secretagogue

Country Status (40)

Country Link
US (2) US6248717B1 (xx)
EP (1) EP0989993B1 (xx)
JP (1) JP3414759B2 (xx)
KR (1) KR100339936B1 (xx)
CN (2) CN1314912A (xx)
AP (1) AP1043A (xx)
AR (1) AR012255A1 (xx)
AT (1) ATE388163T1 (xx)
AU (1) AU744775B2 (xx)
BG (1) BG104024A (xx)
BR (1) BR9810623B1 (xx)
CA (1) CA2294422C (xx)
CO (1) CO4810383A1 (xx)
DE (1) DE69839211T2 (xx)
DK (1) DK0989993T3 (xx)
DZ (1) DZ2538A1 (xx)
EA (1) EA002643B1 (xx)
ES (1) ES2301196T3 (xx)
GT (1) GT199800085A (xx)
HR (1) HRP980362A2 (xx)
HU (1) HUP0002664A3 (xx)
ID (1) ID23188A (xx)
IL (1) IL132810A0 (xx)
IS (1) IS5276A (xx)
MA (1) MA26516A1 (xx)
NO (1) NO996469L (xx)
NZ (1) NZ500658A (xx)
OA (1) OA11241A (xx)
PA (1) PA8453401A1 (xx)
PE (1) PE97599A1 (xx)
PL (1) PL337654A1 (xx)
PT (1) PT989993E (xx)
SK (1) SK177299A3 (xx)
TN (1) TNSN98111A1 (xx)
TR (1) TR199903261T2 (xx)
TW (1) TWI221153B (xx)
UA (1) UA53716C2 (xx)
UY (1) UY25059A1 (xx)
WO (1) WO1998058948A1 (xx)
ZA (1) ZA985541B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6380184B1 (en) 1998-10-28 2002-04-30 Bristol-Myers Squibb Co. Benzoazepines and analogs thereof useful as growth hormone secretagogues
AU759022B2 (en) 1999-02-18 2003-04-03 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US6541634B2 (en) 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US6525203B1 (en) 1999-03-12 2003-02-25 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6518292B1 (en) 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
ATE446758T1 (de) * 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL143690A0 (en) * 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) * 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (en) * 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
JP2004507502A (ja) * 2000-08-30 2004-03-11 ファイザー・プロダクツ・インク 成長ホルモン分泌促進物質のための徐放性製剤
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
IL145540A0 (en) * 2000-09-28 2002-06-30 Pfizer Prod Inc Use of growth hormone secretagogues in conjunction with physical exercise
CN1469871A (zh) * 2000-10-13 2004-01-21 作为生长激素促分泌素的取代的二肽
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
ES2271557T3 (es) 2002-04-09 2007-04-16 Eli Lilly And Company Secretagogos dipeptidicos de la hormona del crecimiento.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
JP2007531739A (ja) * 2004-04-02 2007-11-08 エリクシアー ファーマシューティカルズ， インコーポレイテッド スルホンアミドおよびそれらの使用
KR100641571B1 (ko) * 2005-01-05 2006-10-31 주식회사 팬택앤큐리텔 이동통신 단말기에서의 클럭 발생 장치
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
JP2010518090A (ja) 2007-02-09 2010-05-27 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体修飾因子およびその使用方法
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
CN103764666A (zh) * 2011-06-16 2014-04-30 隆沙有限公司 萃取胜肽的方法及其在液相胜肽合成的应用
CN104010647A (zh) * 2011-11-16 2014-08-27 杜克大学 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
KR102294577B1 (ko) 2015-01-12 2021-08-26 엔터리스 바이오파마, 인크. 고체 경구 제형
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
EP0669830A4 (en) 1992-11-06 1997-02-26 Merck & Co Inc SUBSTITUTED DIPEPTIDE ANALOGS PROMOTING THE RELEASE OF GROWTH HORMONE.
SK282166B6 (sk) 1992-12-11 2001-11-06 Merck & Co., Inc. Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom
CN1174504A (zh) 1993-11-09 1998-02-25 麦克公司 促进生长激素释放的哌啶、吡咯烷和六氢－1h－吖庚因
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
DE69839211T2 (de) 2009-03-19
CN1524857A (zh) 2004-09-01
EA199901076A1 (ru) 2000-08-28
AR012255A1 (es) 2000-09-27
ID23188A (id) 2000-03-23
DZ2538A1 (fr) 2003-02-08
UY25059A1 (es) 2000-12-29
DE69839211D1 (de) 2008-04-17
CA2294422C (en) 2003-07-22
NO996469L (no) 2000-02-23
EP0989993B1 (en) 2008-03-05
ZA985541B (en) 2000-01-10
PA8453401A1 (es) 2000-05-24
JP2000514840A (ja) 2000-11-07
CN1314912A (zh) 2001-09-26
NO996469D0 (no) 1999-12-23
DK0989993T3 (da) 2008-06-02
EP0989993A1 (en) 2000-04-05
HUP0002664A2 (hu) 2000-12-28
GT199800085A (es) 1999-12-10
CA2294422A1 (en) 1998-12-30
AU744775B2 (en) 2002-03-07
AU7445598A (en) 1999-01-04
WO1998058948A1 (en) 1998-12-30
HUP0002664A3 (en) 2001-12-28
PT989993E (pt) 2008-04-15
OA11241A (en) 2003-05-26
TNSN98111A1 (fr) 2005-03-15
MA26516A1 (fr) 2004-12-20
JP3414759B2 (ja) 2003-06-09
ES2301196T3 (es) 2008-06-16
EA002643B1 (ru) 2002-08-29
ATE388163T1 (de) 2008-03-15
BR9810623A (pt) 2000-07-25
TWI221153B (en) 2004-09-21
PL337654A1 (en) 2000-08-28
HRP980362A2 (en) 1999-02-28
TR199903261T2 (xx) 2000-08-21
CO4810383A1 (es) 1999-06-30
SK177299A3 (en) 2001-09-11
NZ500658A (en) 2001-08-31
AP9801266A0 (en) 1998-06-30
BR9810623B1 (pt) 2010-06-15
BG104024A (bg) 2000-07-31
UA53716C2 (uk) 2003-02-17
AP1043A (en) 2002-02-04
US6596867B2 (en) 2003-07-22
IS5276A (is) 1999-11-26
KR20010014153A (ko) 2001-02-26
US6248717B1 (en) 2001-06-19
US20010016570A1 (en) 2001-08-23
KR100339936B1 (ko) 2002-06-10
PE97599A1 (es) 1999-10-12

Similar Documents

Publication Publication Date Title
HUP0002664A3 (en) Tartrate salt of a substituted dipeptide as growth hormone secretagogue
AP9901555A0 (en) Dipeptide compounds which are growth hormone secretagogues
AU7445498A (en) Dipeptide derivatives as growth hormone secretagogues
ZA968989B (en) Polymorphic forms of a growth hormone secretagogue
AU3220097A (en) Sleep quality improvement using a growth hormone secretagogue
PL338883A1 (en) Growth hormone secretion stimulating compounds
EP0669830A4 (en) SUBSTITUTED DIPEPTIDE ANALOGS PROMOTING THE RELEASE OF GROWTH HORMONE.
IL154115A0 (en) Process for the preparation of growth hormone secretagogues
SG74610A1 (en) Method for determination of salt stoichiometry
HUP0003847A3 (en) Basic salts of n-[n-(3,3-dimethylbutyl)-l-alpha-aspartyl]-l-phenylalanine 1-methyl ester
EP0857020A4 (en) FORMULATION OF SECRETAGOGUE STIMULATING THE SECRETION OF THE GROWTH HORMONE, INTENDED TO BE GRANULATED BY WET
HUP9902095A3 (en) New process for the preparation of a growth hormone secretagogue
LT2000026A (en) Acid salts of n-[n-93,3dimethylbutyl0-l-alpha-aspartyl]-l-phenylalanine 1-methyl ester
AU4993497A (en) Convergent process for the preparation of a growth hormone secretagogue
IL160677A0 (en) Tartrate salt of a substituted dipeptide as growth hormone secretagogue
GB9823422D0 (en) Naptho-fused lactams promate release of growth hormone
EP1112282A4 (en) RECEPTOR OF THE GROWTH HORMONE SECRETION PROMOTER FROM THE DOG
HK1017894A1 (en) Polymorphic forms of a growth hormone secretagogue
ZA959777B (en) Bradykinin antagonist peptides containing indane-substituted amino acids
AU4863397A (en) Use of growth hormone or a growth hormone secretagogue for promoting bone formation
GB9603361D0 (en) Polymorphic forms of a growth hormone secretagogue
GB9602949D0 (en) Process for the preparation of a growth hormone secretagogue
AU4464696A (en) Carrier protein driven crystallization of a peptide or polypeptide
GB9603834D0 (en) Amorphous form of a growth hormone secretagogue
GB9625815D0 (en) Convergent process for the preparation of a growth hormone secretagogue